Get the Stockscreener App
1.67
2.91%
-0.05
After Hours:
1.68
0.01
+0.60%
Equillium Inc stock is traded at $1.67, with a volume of 137.73K.
It is down -2.91% in the last 24 hours and down -23.39% over the past month.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
See More
Previous Close:
$1.72
Open:
$1.7
24h Volume:
137.73K
Relative Volume:
0.21
Market Cap:
$105.89M
Revenue:
$4.39M
Net Income/Loss:
$-22.40M
P/E Ratio:
-3.2758
EPS:
-0.5098
Net Cash Flow:
$-22.79M
1W Performance:
-13.02%
1M Performance:
-23.39%
6M Performance:
-18.93%
1Y Performance:
+19.29%
1-Day Range:
$1.66
$1.71
1-Week Range:
$1.65
$1.98
52-Week Range:
$0.7562
$3.54
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
1.67 | 105.89M | 4.39M | -22.40M | -22.79M | -0.5098 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-26 | Initiated | Oppenheimer | Outperform |
| Apr-16-26 | Initiated | B. Riley Securities | Buy |
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Apr-07-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504 - Yahoo Finance
Equillium, Inc. (EQ) Stock Price History & Data - Traders Union
Equillium, Inc. (EQ) Earnings Date, Reports and Estimates - Traders Union
Live Equillium, Inc. (EQ) Technical Analysis - Traders Union
Equillium at Stifel 2026 Virtual Immunology and Inflammation Forum: pipeline advances - Investing.com Canada
Equillium, Inc.(NasdaqCM: EQ) added to S&P Global BMI Index - marketscreener.com
Equillium Stock Price Forecast. Should You Buy EQ? - StockInvest.us
Equillium Inc (NASDAQ: EQ) Share Price, EQ Stock News, EQ Share Price & Updates - kalkine.ca
Equillium, Inc. Stock Price Today | EQ Live Chart & News - Traders Union
Roth MKM Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Equillium, Inc. (0A4D.IL) Latest Stock News & Headlines - Yahoo Finance
Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire
Equillium at Cantor conference: EQ504 advances as lead ahr program By Investing.com - Investing.com Nigeria
8-K: Equillium | 8-K: Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - Moomoo
EQ Reiterates by Roth Capital -- Price Target Maintained at $12 - GuruFocus
EQ Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Momentum Score - vinanet.vn
Equillium to Participate in Upcoming Investor Conferences - GlobeNewswire
EQ | Equillium, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Equillium (EQ) Q1 2026 Earnings: The EPS Result Is Below Expectation in the Available Record; Closing Reaction: Shares Finish 0.85% Lower at the CloseEarnings Acceleration Picks - vinanet.vn
Equillium (EQ) Earnings Report: EPS Misses Its Estimate in the Latest Session; Trading Response - vinanet.vn
3 Promising Penny Stocks With Market Caps Under $400M - simplywall.st
Equillium (NASDAQ:EQ) Rating Increased to Hold at Wall Street Zen - MarketBeat
Oppenheimer Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $7 - Moomoo
EQ Q1 2026 Earnings: EPS Miss of 34.5% Drives 7.8% Stock DeclineDividend Increase Stocks - vinanet.vn
Equillium (NASDAQ:EQ) Announces Earnings Results - MarketBeat
Equillium Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Equillium Inc For: 13 August By Investing.com - Investing.com Nigeria
Equillium Inc. (EQ) Drops 7.8% to $2.01 as Support at $1.91 Comes Into FocusKAMA Signal - vinanet.vn
Equillium, Inc. Q2 2026: Net loss $(4.7)M, EPS $(0.04) — 10-Q Summary - TradingView
Equillium Q2 post narrower net loss than expected; starts R&D initiatives - TradingView
Equillium, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Affinity Asset Advisors reports 4.1M Equillium (EQ) shares, a 6.5% stake - Stock Titan
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
EQ Q1 2026 Earnings: EPS Misses Estimates with Wider-than-Expected Loss of -$0.06Fiscal Year Earnings - vinanet.vn
Equillium (NASDAQ:EQ) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
Adage Capital discloses 7.25% Equillium (EQ) stake via Schedule 13G/A filing - Stock Titan
EQ Q1 2026 Earnings: Wider-than-Expected Loss Leaves Shares LowerDividend Earnings Report - careplusvn.com
EQ Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Equillium Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Equillium Inc (EQ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Equillium (EQ) Holds Near $2.11 as Stock Tests $2.0 SupportGap and Go - careplusvn.com
Equillium (EQ) Projected to Announce Earnings on Thursday - MarketBeat
EQ Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Equillium, Inc. $EQ Holdings Lifted by Janus Henderson Group PLC - MarketBeat
Clear Street Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $9 - Moomoo
EQ Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares Down 5.17%Margin Expansion Trends - careplusvn.com
Equillium Inc. (EQ) Shows Modest Gain as Shares Test Key ResistanceHigh Volume Node - dars.gov.et
ADAR1 Capital Management LLC Has $7.45 Million Position in Equillium, Inc. $EQ - MarketBeat
1,498,993 Shares in Equillium, Inc. $EQ Purchased by Eversept Partners LP - MarketBeat
EQ|Equillium Inc|Price:2.455|Chg%:-0.035 - TradingKey
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):